Aerovate Therapeutics, Inc.
AVTE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.84 | -0.00 | 4.80 | 1.85 |
| FCF Yield | -0.60% | -1.38% | -0.09% | -0.42% |
| EV / EBITDA | -145.53 | -88.08 | -738.83 | -409.75 |
| Quality | ||||
| ROIC | -15.21% | -13.73% | -4.49% | -8.41% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.88 | 0.54 | 0.95 | 2.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 481,928.45% | 481,928.45% | 481,928.45% | 481,928.45% |
| Free Cash Flow Growth | 39.51% | -1,440.15% | 78.45% | 31.14% |
| Safety | ||||
| Net Debt / EBITDA | 1.96 | 7.93 | 12.96 | 5.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -360.00 |